1P-ETH-LAD
1-propanoyl-6-ethyl-6-nor-lysergic acid diethylamide
1Provenance card
the boundary, as counts
Sources
3231 with DOI
8 strong · 21 moderate · 3 weak
Compilations
12026-05-11T08:13:09.343Z
pipeline-v5 · prompt hash not recorded — run predates 2026-09
Decisions
30last ruled 2026-06-04
0 awaiting a ruling
Issued documents
62026-10-19T20:28:52.380Z
notice · info card · emergency
Searches
271 with no results
queries and counts on the build
Claims checked
7654 supported
54 supported · 22 not
Correspondence
0received
consent field ships in Phase 4
Edges
258
derivations recorded for this entity
Complete over 32 sources, 1 compilation, and 30 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/1p-eth-lad/archive
Timeline
what happened, newest first — claims, searches and artifacts stay inside Build
- 2026-10-19issueIssued emergency
- 2026-10-19issueIssued info_card
- 2026-10-19issueIssued notice
- 2026-09-07srcAbsolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover Study
- 2026-09-07srcPsychedelics as Medicines: An Emerging New Paradigm
- 2026-09-07srcReturn of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)
- 2026-09-07srcReturn of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)
- 2026-09-07srcReturn of the lysergamides. Part III: Analytical characterization of ETH-LAD and 1P-ETH-LAD
- 2026-09-07srcReturn of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)
- 2026-09-07srcReturn of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD)
- 2026-09-07srcReturn of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)
- 2026-09-07srcPharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration
- 2026-09-07srcAnalytical and behavioral characterization of N-ethyl-N-isopropyllysergamide (EIPLA), an isomer of ETH-LAD
- 2026-09-07srcGenie in a blotter: A comparative study of LSD and LSD analogues' effects and user profile
- 2026-09-07srcA Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD
- 2026-09-07srcChemistry and Structure-Activity Relationships of Psychedelics.
- 2026-09-07srcDesigner drugs: mechanism of action and adverse effects
- 2026-09-07srcFlashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants
- 2026-09-07srcIn vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures
- 2026-09-07srcTapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles
- 2026-09-07srcHallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes
- 2026-09-07srcPharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD)
- 2026-09-07src5-HT2A receptors: Pharmacology and functional selectivity
- 2026-09-07srcSynthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives
- 2026-09-07srcIdentification of 5-HT2A receptor signaling pathways associated with psychedelic potential
- 2026-09-07srcGenetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis
- 2026-09-07srcPharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review
- 2026-09-07srcPharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide administration in healthy participants
- 2026-09-07srcSerotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants?
- 2026-09-07src[Identification and Analysis of LSD Derivatives in Illegal Products as Paper Sheet]
- 2026-09-07srcPsychedelics and the human receptorome
- 2026-09-07srcPsychedelics and mental health: a population study
- 2026-09-07srcHallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives
- 2026-09-07srcHallucinogen-Induced Persisting Perception Disorder: A Case Report
- 2026-09-07srcCayman Chemical: 1P-ETH-LAD Solution (CAS 2230715-45-2)
- 2026-09-04issueIssued emergency
- 2026-09-04issueIssued info_card
- 2026-09-04issueIssued notice
- 2026-06-04proposal28 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
- 2026-06-04publicationPublication — backfill
- 2026-05-11revisionRevision 1
- 2026-05-11absenceSearched ClinicalTrials.gov for "1P-ETH-LAD lysergamide" — no results
- 2026-05-11genGeneration — pipeline-v5 · with 3 morepipeline-v5
- 2026-05-11rungeneration run
The same entries, as forms: six forms.